Statins are now among the most widely used drugs in the world. They have proven efficacy in treating hyperlipidemia and in the prevention of vascular disease, with randomized data showing that they confer benefits in terms of clinical outcomes, including mortality. However, no drugs are without their adverse effects. The most well-known adverse effect of statins is probably muscle toxicity, which led to the worldwide withdrawal of cerivastatin. More recently, the use of statins has been linked to the occurrence of type 2 diabetes [1] .
In this issue of Clinical Infectious Diseases, in a population-based cohort study of individuals aged ≥65 years, Antoniou et al [2] show that the use of statins was associated with a higher risk (hazard ratio, 1.13 [95% confidence interval, 1.10-1.17]) of reactivation of latent varicellazoster virus (VZV) infection. Although the absolute risk was low, the attributable fraction was high, with the authors estimating that 20 000 cases of herpes zoster per year in the United States could be attributable to the use of statins. However, before one accepts the findings and recommendations, it is important to evaluate strengths and limitations of the study, as well as the underlying biological rationale.
The strengths of the study include the use of a well-characterized database that has been widely employed for pharmacoepidemiology studies; the careful design with adequate numbers of subjects who were exposed to statins and subsequent events; and the use of propensity analysis, a balancing score to ensure that the cases and controls are well matched at baseline [3] , to reduce the risk of confounding. However, in any observational study, there is a residual risk of unforeseen confounding, particularly when the risk is as low as 13% above baseline. Some limitations of the study include the inability to define a dose-response relationship as most patients did not have a change in dose, and the use of statins as a class, as the individual compounds vary widely in their physical properties and pharmacokinetics and thus may have differential effects.
What about the underlying biological plausibility? Statins are known to have an immunomodulatory action that is thought to be important in their efficacy in atherosclerotic disease, in addition to their primary effect of lowering cholesterol. Because the severity of the tissue damage associated with many infections is also dependent on the vigor of the host immune response, the use of statins has been suggested for patients with various infectious diseases. For instance, a recent phase II trial in sepsis suggested that prior use of atorvastatin was associated with improved survival [4] , whereas a meta-analysis has shown that statins may be beneficial in community-acquired pneumonia [5] . By contrast, another observational study showed that statins were associated with an increased incidence of some infections [6] . Although many of the studies in the literature have studied large patient cohorts to determine the association between statin use and outcomes from various infections (including the prevention of infections), they have the same underlying potential issue of confounding as the article by Antoniou et al [2] . There is therefore a need for definitive randomized trials to determine whether statins are beneficial (or deleterious) in either preventing and/or reducing adverse clinical outcomes in patients with various infections.
The effects of statins on the body's immune system and inflammatory processes are complex, being the result of multiple modes of action [7] . Furthermore, they are likely to vary between individuals because of differences in underlying comorbidities, concomitant drug therapy, and individual factors including age. It is known that cell-mediated immunity, which protects against VZV reactivation, tends to wane with age [8] . Statins have immunosuppressive properties, and thus much like steroids and anti-tumor necrosis factor (TNF) agents [9] , could predispose to reactivation of VZV. However, the immunosuppression caused by statins is clearly not as pronounced as that seen with steroids and anti-TNF agents, but whether this varies in different individuals is unclear. Given the pleiotropic effects of statins, it is thus theoretically possible that they could cause reactivation of VZV in predisposed individuals.
The final issue to consider is the role of cholesterol itself. A study of 12 patients after heart transplant showed that patients who developed herpes zoster had higher cholesterol levels within 1 month of the episode compared to controls [10] . There are no studies examining the relationship between serum cholesterol levels and VZV, and unfortunately, the study by Antoniou et al [2] did not have data on serum cholesterol prior to the development of herpes zoster.
In summary, Antoniou et al [2] , in a well-conducted study, have shown that statins may have the potential to cause VZV reactivation, but because of the issue of confounding and the lack of a definitive mechanism, there is a need for replication of the study findings in a different pharmacoepidemiologic database. The authors [2] also suggest the use of herpes zoster vaccine in patients requiring statin therapy. Indeed, this is already recommended in elderly patients irrespective of statin use. For instance, the US Centers for Disease Control and Prevention currently recommends that the vaccine should be used in all patients aged >60 years, and the UK Department of Health has recently recommended the use of the vaccine in patients aged >70 years. The take-home message is that statins are still a highly beneficial group of drugs in patients with atherosclerotic arterial disease, and their use in any patient group should be based on a careful evaluation of the individual benefits and risks.
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